

Amendments to the Specification

Please add the following paragraph on page 1 after the title “NITROGEN-CONTAINING AROMATIC DERIVATIVES”:

Related Applications

The present application claims priority to PCT application, PCT/JP03/01964, filed August 23, 2003, which claims priority to Japanese patent application 2002-253123, filed August 30, 2002, and U.S. provisional patent application, U.S.S.N. 60/464,690, filed April 22, 2003; each of which is incorporated herein by reference.

Please replace the first three lines of paragraph [0010] on page 4 with the following amended lines:

Specifically, the present invention provides the following following:

<1> a compound (except N1-cyclopropyl-5-((2(((2-chloroethylamino)carbonyl)amino)-4-pyridyl)oxy)-1H-1-indolecarboxamide) represented by the general formula:

Please replace the line 18 on page 9 with the following amended line:

<2> a compound (except N1-cyclopropyl-5-((2(((2-chloroethylamino)carbonyl)amino)-4-pyridyl)oxy)-1H-1-indolecarboxamide) represented by the general formula:

Please replace the subtitle “**Best mode for carrying out the Invention**” on page 40, line 22, with the following subtitle:

Detailed Description of the Invention

Please replace Table 1 in paragraph [0147] on page 108 with the following amended Table 1:

[Table 1]

Example No.	VEGF-stimulated tube formation IC ₅₀ (nM)	FGF2-stimulated tube formation IC ₅₀ (nM)
39	5.1	470
41	2.1	250
46	7.0	470
47	5.8	120
53	6.7	440
78	3.0	450
<u>ref. 1</u>	<u>35</u>	<u>>10000</u>

Please replace Table 2 in paragraph [0153] on page 115 with the following amended Table 2:

[Table 2]

Example No.	VEGFR2 kinase IC ₅₀ (nM)	FGFR1 kinase IC ₅₀ (nM)	Example No.	VEGFR2 kinase IC ₅₀ (nM)	FGFR1 kinase IC ₅₀ (nM)
7	8.0	26	68	37	52
11	3.0	47	79	9.8	25
18	3.0	70	81	12	38
28	4.5	4.1	82	15	24
32	9.3	16	88	14	24
33	7.1	12	104	3.9	19
34	8.4	22	116	14	87
36	3.4	16	119	21	120
37	4.8	1.2	139	6.3	190
39	4.5	6.3	206	4.1	3.5
40	5.7	6.9	207	4.6	12
41	6.1	3.2	208	7.7	6.8
43	6.4	18	209	17	29
44	7.7	14	210	8.1	40

46	32	12	211	45	36
47	40	21	212	8.6	19
50	5.0	13	213	10	330
53	3.8	2.1	<u>ref. 1</u>	<u>45</u>	<u>600</u>

Please replace paragraph [0516] on page 411 with the following amended paragraph:

Example 222 Reference Example 1

N1-Cyclopropyl-5-((2-(((2-chloroethylamino)carbonyl)amino)-4-pyridyl)oxy)-1H-1-indolecarboxamide

N1-cyclopropyl-5-((2-amino-4-pyridyl)oxy)-1H-1-indolecarboxamide (400 mg, CAS No. 417722-12-4) described in WO02/32872, 2-chloroethyl isocyanate (150 mg) and tetrahydrofuran (5 ml) were stirred at 80 °C for 1.5 hours. The mixture was cooled to room temperature, silica gel was added, and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (hexane : ethyl acetate = 1 : 1, followed by ethyl acetate) to yield 280 mg of a colorless powder.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.57-0.63 (2H, m), 0.70-0.75 (2H, m), 2.73-2.80 (1H, m), 3.42 (2H, q, J= 6.0Hz), 3.61 (2H, t, J= 6.0Hz), 6.52 (1H, dd, J= 5.6Hz, 2.4Hz), 6.65 (1H, d, J= 3.6Hz), 6.85 (1H, d, J= 2.4Hz), 7.04 (1H, dd, J= 8.8Hz, 2.4Hz), 7.35 (1H, d, J= 2.4Hz), 7.86 (1H, d, J= 3.6Hz), 8.04 (1H, d, J= 5.6Hz), 8.27 (1H, s), 8.28 (1H, d, J= 8.8Hz), 8.34 (1H, brs), 9.19 (1H, s).

Please replace paragraph [0517] on page 412 with the following amended paragraph:

The structural formulas of the compounds obtained in ~~Production examples and Examples~~ Production Examples, Examples, and Reference Example above are shown in Tables 5 to 17 below.

Please replace “Example 222” in Table 17 on page 425, with “Reference Example 1”.